# Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

> **NCT00082836** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00082836
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2013-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082836, "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00082836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*